Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Ade

Internal Medicine Moline, IL Medical Doctor

NPI 1972589042 CMS profile 362047

600 John Deere Rd, Moline, IL 61265

Open in the dashboard

General payments

$5,909

412 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Ade of Moline, IL is reported in the CMS Open Payments database as having received $5,909 across 412 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39 3
2024 General $213 10
2023 General $1,276 70
2022 General $1,452 121
2021 General $1,812 138
2020 General $716 50
2019 General $400 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Ade
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to David Ade were reported at $39. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year David Ade Internal Medicine median Middle half National median
2019 $400 $159 $48–$570 $163
2020 $716 $119 $33–$402 $114
2021 $1,812 $135 $37–$521 $132
2022 $1,452 $141 $42–$496 $149
2023 $1,276 $149 $45–$519 $160
2024 $213 $154 $47–$537 $164
2025 $39 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $888 47 payments
  2. Amgen Inc. $562 30 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $430 36 payments
  4. AbbVie, Inc. $379 41 payments
  5. Astellas Pharma US Inc $310 7 payments
  6. Ironwood Pharmaceuticals, Inc $254 36 payments
  7. GlaxoSmithKline, LLC. $251 19 payments
  8. Pfizer Inc. $230 16 payments
  9. Allergan Inc. $220 21 payments
  10. Novo Nordisk Inc $182 13 payments
  11. Other $2,202 146 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,646 408 payments
  2. Education $262 4 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $412 18 payments
  2. Repatha $290 13 payments
  3. Prolia $286 18 payments
  4. BREZTRI $260 11 payments
  5. EVENITY $257 16 payments
  6. Linzess $254 36 payments
  7. FASENRA $228 8 payments
  8. JARDIANCE $210 14 payments
  9. TRELEGY ELLIPTA $172 13 payments
  10. AIMOVIG $171 11 payments
  11. Other $5,032 379 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 210 drugs

Part D claims

20,700

Median for Internal Medicine: 777

Drug cost

$1,146,970

Median for Internal Medicine: $73,373

Branded share of claims

15.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 211 $185,246
Jardiance Empagliflozin Brand 95 $120,667
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 75 $89,062
Xeljanz Xr Tofacitinib Citrate Brand 11 $62,698
Ozempic Semaglutide Brand 44 $56,320
Myrbetriq Mirabegron Brand 57 $50,237
Xarelto Rivaroxaban Brand 44 $42,533
Januvia Sitagliptin Phosphate Brand 31 $37,478
Farxiga Dapagliflozin Propanediol Brand 31 $27,776
Trulicity Dulaglutide Brand 13 $25,525

The 10 drugs with the highest cost, of 210 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$281,690

Of which drugs: $22,751

Medicare patients

719

Average age 74

Services billed

43,601

360 women, 359 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 38%
Diabetes 29%
Chronic kidney disease 22%
Depression 18%
Heart failure 15%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 40 40 $11,417
Vaccine for influenza for injection into muscle 90662 Office 119 122 $9,883
Injection, testosterone cypionate, 1 mg J1071 Office 11 37,501 $638
Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older 90715 Office 21 21 $504
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 22 197 $168

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
HADLIMA
  • Organon LLC $30
$30 — —
Xhance
  • OptiNose US, Inc. $23
$23 — —
VRAYLAR
  • AbbVie, Inc. $22
$22 — —
Bimzelx
  • UCB, Inc. $22
$22 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

412 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record